Influenza virosomes as vaccine adjuvant and carrier system

Expert Review of Vaccines

Volumn 12, Issue 7, 2013, Pages 779-791

  Moser, Christian ^a   Müller, Matthias ^a   Kaeser, Matthias D ^a   Weydemann, Ulrike ^b   Amacker, Mario ^a  

^a Pevion Biotech AG   (Switzerland)

^b IP Services   (Germany)

Author keywords

adjuvant; antigen delivery; carrier; influenza; vaccines; virosomes; VLP

Indexed keywords

ADJUVANT; CANCER VACCINE; CANDIDA ALBICANS VACCINE; DETERGENT; HEPATITIS A VACCINE; HEPATITIS C VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; LIPOSOME; MALARIA VACCINE; NASALFLU; UNCLASSIFIED DRUG; VIROSOME;

BREAST CANCER; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL (TOPIC); CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; FREEZE DRYING; GOOD MANUFACTURING PRACTICE; HEPATITIS A; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; INFECTION PREVENTION; INFLUENZA VIRUS; LIPOSOMAL DELIVERY; MALARIA; MALARIA FALCIPARUM; NONHUMAN; PRIORITY JOURNAL; REVIEW; THIN LAYER CHROMATOGRAPHY; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; DRUG CARRIERS; HUMANS; ORTHOMYXOVIRIDAE; VACCINES; VACCINES, VIRUS-LIKE PARTICLE; VIROSOMES;

EID: 84880897333     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.811195     Document Type: Review

References (87)

1. Almeida JD, Edwards DC, Brand CM, Heath TD. Formation of virosomes from influenza subunits and liposomes. Lancet 2(7941), 899-901 (1975
2. Morein B, Helenius A, Simons K, Pettersson R, Kääriäinen L, Schirrmacher V. Effective subunit vaccines against an enveloped animal virus. Nature 276(5689), 715-718 (1978
3. Johnson JE, Chiu W. Structures of virus and virus-like particles. Curr. Opin. Struct. Biol. 10(2), 229-235 (2000
4. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol. Chem. 389(5), 521-536 (2008
5. Grgacic EV, Anderson DA. Virus-like particles: Passport to immune recognition. Methods 40(1), 60-65 (2006
6. Bachmann MF, Jennings GT. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10(11), 787-796 (2010
7. Buonaguro F, Buonaguro L. The application of virus-like particles to human diseases. Expert Rev. Vaccines 12(2), 99 (2013
8. Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev. Vaccines 10(11), 1569-1583 (2011
9. Kaneda Y. Virosome: A novel vector to enable multi-modal strategies for cancer therapy. Adv. Drug Deliv. Rev. 64(8), 730-738 (2012
10. Waelti E, Wegmann N, Schwaninger R et al. Targeting her-2/neu with antirat Neu virosomes for cancer therapy. Cancer Res. 62(2), 437-444 (2002
11. Felnerova D, Viret JF, Glück R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 15(6), 518-529 (2004
12. Waelti ER, Glück R. Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipidreconstituted influenza-virus envelopes (cationic virosomes). Int. J. Cancer 77(5), 728-733 (1998
13. Schoen P, Chonn A, Cullis PR, Wilschut J, Scherrer P. Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene Ther. 6(5), 823-832 (1999
14. Cusi MG, Gluck R. Potential of DNA vaccines delivered by influenza virosomes. Vaccine 18(15), 1435 (2000
15. Cusi MG, Terrosi C, Savellini GG, Di Genova G, Zurbriggen R, Correale P. Efficient delivery of DNA to dendritic cells mediated by influenza virosomes. Vaccine 22(5-6), 735-739 (2004
16. de Jonge J, Holtrop M, Wilschut J, Huckriede A. Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther. 13(5), 400-411 (2006
17. de Jonge J, Leenhouts JM, Holtrop M et al. Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. Biochem. J. 405(1), 41-49 (2007
18. Huckriede A, De Jonge J, Holtrop M, Wilschut J. Cellular delivery of siRNA mediated by fusion-Active virosomes. J. Liposome Res. 17(1), 39-47 (2007
19. Lund PE, Hunt RC, Gottesman MM, Kimchi-Sarfaty C. Pseudovirions as vehicles for the delivery of siRNA. Pharm. Res. 27(3), 400-420 (2010
20. Jamali A, Holtrop M, de Haan A et al. Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination. Immunol. Lett. 148(1), 77-82 (2012
21. Stegmann T, Morselt HW, Booy FP, van Breemen JF, Scherphof G, Wilschut J. Functional reconstitution of influenza virus envelopes. EMBO J. 6(9), 2651-2659 (1987
22. Glück R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ Jr. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 90(6), 2491-2495 (1992
23. Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: Production. Vaccine 20(Suppl. 5), B17-B23 (2002
24. Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344(8916), 160-163 (1994
25. Conne P, Gauthey L, Vernet P et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 15(15), 1675-1679 (1997
26. Herzog C, Hartmann K, Künzi V et al. Eleven years of Inflexal V -A virosomal adjuvanted influenza vaccine. Vaccine 27(33), 4381-4387 (2009
27. Bovier PA. Epaxal: A virosomal vaccine to prevent hepatitis A infection. Expert Rev. Vaccines 7(8), 1141-1150 (2008
28. Glück R. Intranasal immunization against influenza. J. Aerosol Med. 15(2), 221-228 (2002
29. Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350(9), 896-903 (2004
30. Zurbriggen R, Novak-Hofer I, Seelig A, Glück R. IRIV-Adjuvanted hepatitis A vaccine: In vivo absorption and biophysical characterization. Prog. Lipid Res. 39(1), 3-18 (2000
31. Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine 21(9-10), 921-924 (2003
32. Huckriede A, Bungener L, Stegmann T et al. The virosome concept for influenza vaccines. Vaccine 23(Suppl. 1), S26-S38 (2005
33. Moser C, Amacker M, Zurbriggen R. Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev. Vaccines 10(4), 437-446 (2011
34. Zurbriggen R, Glück R. Immunogenicity of IRIV-versus alum-Adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine 17(11-12), 1301-1305 (1999
35. Amacker M, Moese S, Kammer AR, Helenius A, Zurbriggen R. Influenza virosomes as delivery systems for antigens. In: Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids, and Vaccines. Jorgensen L, Nielsen HM (Eds). John Wiley & Sons Ltd, West Sussex, UK, 377-393 (2009
36. De Bernardis F, Amacker M, Arancia S et al. A virosomal vaccine against candidal vaginitis: Immunogenicity, efficacy and safety profile in animal models. Vaccine 30(30), 4490-4498 (2012
37. Amacker M, Engler O, Kammer AR et al. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int. Immunol. 17(6), 695-704 (2005
38. Kammer AR, Amacker M, Rasi S et al. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine 25(41), 7065-7074 (2007
39. Bungener L, Serre K, Bijl L et al. Virosomemediated delivery of protein antigens to dendritic cells. Vaccine 20(17-18), 2287-2295 (2002
40. Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T. Virosome-mediated delivery of protein antigens in vivo: Efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 23(10), 1232-1241 (2005
41. Künzi V, Dornseiff M, Horwath J, Hartmann K. Safe vaccination of children with a virosomal adjuvanted influenza vaccine. Vaccine 27(8), 1261-1265 (2009
42. Frösner G, Steffen R, Herzog C. Virosomal hepatitis a vaccine: Comparing intradermal and subcutaneous with intramuscular administration. J. Travel Med. 16(6), 413-419 (2009
43. Wang BZ, Xu R, Quan FS, Kang SM, Wang L, Compans RW. Intranasal immunization with influenza VLPs incorporating membrane-Anchored flagellin induces strong heterosubtypic protection. PLoS ONE 5(11), e13972 (2010
44. Pedersen GK, Ebensen T, Gjeraker IH et al. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS ONE 6(11), e26973 (2011
45. Mallick AI, Parvizi P, Read LR, Nagy E, Behboudi S, Sharif S. Enhancement of immunogenicity of a virosome-based avian influenza vaccine in chickens by incorporating CpG-ODN. Vaccine 29(8), 1657-1665 (2011
46. Mallick AI, Kulkarni RR, St Paul M et al. Vaccination with CpG-Adjuvanted avian influenza virosomes promotes antiviral immune responses and reduces virus shedding in chickens. Viral Immunol. 25(3), 226-231 (2012
47. Radosevic K, Rodriguez A, Mintardjo R et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: Impact of distinct additional adjuvants. Vaccine 26(29-30), 3640-3646 (2008
48. Cox RJ, Pedersen G, Madhun AS et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 29(45), 8049-8059 (2011
49. Leroux-Roels G, Maes C, Clement F et al. Randomized phase i: Safety, immunogenicity and mucosal antiviral activity in young healthy women vaccinated with HIV-1 Gp41 P1 peptide on virosomes. PLoS ONE 8(2), e55438 (2013
50. Bomsel M, Tudor D, Drillet AS et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34(2), 269-280 (2011
51. Vacher G, Gremion C, Moser C, Stoffel SA, Amacker M, Zurbriggen R, Gurny R, Borchard G. Virosomal C. albicans vaccine for vaginal application: Formulation development and toxicity/ immunogenicity studies. J. Drug Del. Sci. Tech. 22(5), 447-452 (2012
52. de Jonge J, Amorij JP, Hinrichs WL, Wilschut J, Huckriede A, Frijlink HW. Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. Eur. J. Pharm. Sci. 32(1), 33-44 (2007
53. Angel J, Chaperot L, Molens JP et al. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine 25(19), 3913-3921 (2007
54. Schumacher R, Adamina M, Zurbriggen R et al. Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine 22(5-6), 714-723 (2004
55. Van Der Wielen M, Vertruyen A, Froesner G et al. Immunogenicity and safety of a pediatric dose of a virosomeadjuvanted hepatitis A vaccine: A controlled trial in children aged 1-16 years. Pediatr. Infect. Dis. J. 26(8), 705-710 (2007
56. Peduzzi E, Westerfeld N, Zurbriggen R, Pluschke G, Daubenberger CA. Contribution of influenza immunity and virosomalformulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial. Clin. Immunol. 127(2), 188-197 (2008
57. Genton B, Pluschke G, Degen L et al. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosomeformulated synthetic peptides in healthy adult volunteers. PLoS ONE 2(10), e1018 (2007
58. Thompson FM, Porter DW, Okitsu SL et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS ONE 3(1), e1493 (2008
59. Cech PG, Aebi T, Abdallah MS et al. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: Randomized Phase 1b trial in semi-immune adults & children. PLoS ONE 6(7), e22273 (2011
60. Wiedermann U, Wiltschke C, Jasinska J et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/ neu-specific immune responses in patients with metastatic breast cancer: A phase I study. Breast Cancer Res. Treat. 119(3), 673-683 (2010
61. Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15(11), 1209-1213 (1997
62. Bovier PA. Recent advances with a virosomal hepatitis A vaccine. Expert Opin. Biol. Ther. 8(8), 1177-1185 (2008
63. Abarca K, Ibá;nd;ez I, de la Fuente P et al. Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1-16 years. Vaccine 29(48), 8855-8862 (2011
64. Glück R, Wälti E. Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV). Dev. Biol. (Basel) 103, 189-197 (2000
65. Hatz C, van der Ploeg R, Beck BR, Frösner G, Hunt M, Herzog C. Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years. Clin. Vaccine Immunol. 18(5), 885-887 (2011
66. Lewis DJ, Huo Z, Barnett S et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 4(9), e6999 (2009
67. de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. Antibody induction by virosomal, MF59-Adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 26(1), 119-127 (2007
68. de Bruijn IA, Nauta J, Gerez L, Palache AM. Virosomal influenza vaccine: A safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res. 103(1-2), 139-145 (2004
69. de Bruijn IA, Nauta J, Gerez L, Palache AM. The virosomal influenza vaccine Invivac: Immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects. Vaccine 24(44-46), 6629-6631 (2006
70. Okitsu SL, Silvie O, Westerfeld N et al. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS ONE 2(12), e1278 (2007
71. Tamborrini M, Stoffel SA, Westerfeld N et al. Immunogenicity of a virosomallyformulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malar. J. 10, 359 (2011
72. Hunziker IP, Zurbriggen R, Glueck R et al. Perspectives: Towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol. 38(6), 475-484 (2001
73. Murphy CG, Fornier M. HER2-positive breast cancer: Beyond trastuzumab. Oncology (Williston Park, N.Y.) 24(5), 410-415 (2010
74. Wiedermann U, Davis AB, Zielinski CC. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. Breast Cancer Res. Treat. 138(1), 1-12 (2013
75. Tudor D, Derrien M, Diomede L et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: An IgA gene and functional analysis. Mucosal Immunol. 2(5), 412-426 (2009
76. Sandini S, La Valle R, Deaglio S, Malavasi F, Cassone A, De Bernardis F. A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine. FEMS Immunol. Med. Microbiol. 62(2), 215-224 (2011
77. Cassone A. Candida vaccines: Progress and challenges. Presented at: 11th ASM Conference on Candida and Candidiasis. San Francisco, CA, USA, 1 April 2012
78. Amacker M. Managing Change from Bench to CTM Production. Presented at: The Immunotherapeutics and Vaccine Summit. Cambridge, MA, USA, 18 August 2012
79. Moser C, Amacker M, Kammer AR, Rasi S, Westerfeld N, Zurbriggen R. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev. Vaccines 6(5), 711-721 (2007
80. Khoshnejad M, Young PR, Toth I, Minchin RF. Modified influenza virosomes: Recent advances and potential in gene delivery. Curr. Med. Chem. 14(29), 3152-3156 (2007
81. Daemen T, de Mare A, Bungener L, de Jonge J, Huckriede A, Wilschut J. Virosomes for antigen and DNA delivery. Adv. Drug Deliv. Rev. 57(3), 451-463 (2005
82. Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS ONE 7(5), e36812 (2012
83. Influenza vaccine (surface antigen, inactivated, virosome). European Pharmacopoeia 7.8 793-795 (2013
84. Hepatitis A vaccine (inactivated, virosome). European Pharmacopoeia 7.8, 781-784 (2013
85. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38(5), 1404-1413 (2008
86. Kaeser MD. Manufacturing and QC of virosomal vaccines. Presented at: Virus-like Particle & Nano-particle Vaccines VLPNPV. Cannes, France, 29 November 2012
87. Holzer BR, Hatz C, Schmidt-Sissolak D, Glück R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-Adsorbed hepatitis A vaccine: A randomized controlled trial. Vaccine 14(10), 982-986 (1996